Clinical trials: Antipsychotic
Schizophrenia, Schizoaffective Disorder
Pregnenolone and L-theanine Augmentation in the Treatment for Schizophrenia and Schizoaffective Disorders
Schizophrenia (SZ) and schizoaffective (SA) disorders are comprised of several debilitating symptoms. It was suggested that compounds with neuroprotective effects might be useful in the management of SZ/SA symptoms.
- Trial name
- NCT01831986
- Testing
- Pregnenolone and L-Theanine
- Volunteers
- 60 people
- Sponsor
- Sha'ar Menashe Mental Health Center
Severe Mental Disorder, Metabolic Complication
Effectiveness of a Pragmatic, Metabolic Care Clinic for Patients With Severe Mental Illness - The Meta Care Clinic
This study will examine the effectiveness of a Pragmatic, Metabolic Care Clinic for Patients With Severe Mental Illness
- Conditions
- Severe Mental Disorder, Metabolic Complication, Side-Effect;Medication, Schizophrenia Spectrum and Other Psychotic Disorders
- Trial name
- NCT06624462
- Testing
- Treatment in the Meta Care Clinic, Standard care with general practitioner and/or outpatient clinics
- Where
- Denmark
- Volunteers
- 84 people
- Sponsor
- Bjorn H. Ebdrup
Depression, Affective Disorders, Psychotic
Routine Plasma Level Determination to Compare Actual vs Expected Plasma Levels at Psychiatric Inpatient Admission
Compliance with treatment is notoriously low in psychiatric patients. Traditional methods of monitoring compliance, however, may underreport nonadherence to treatment.
- Trial name
- NCT00627510
- Testing
- Routine psychiatric inpatient treatment
- Where
- Austria
- Volunteers
- 161 people
- Sponsor
- Medical University Innsbruck
Diabetes
Metabolic Effects of Antipsychotic Substitution in Children
This project aims to identify whether therapeutic substitution of aripiprazole for risperidone or olanzapine, combined with standard nutrition intervention, will impact the metabolic changes associated with antipsychotic…
- Trial name
- SMEAC (NCT00910780)
- Testing
- Aripiprazole, Zyprexa, Risperdal
- Sponsor
- Washington University School of Medicine
Schizophrenia, Schizoaffective Disorder
Research Into Antipsychotic Discontinuation and Reduction Trial
Psychosis and schizophrenia are common and costly mental health problems. Psychosis is the name given to a group of mental conditions in which cause people to perceive or interpret things differently from those around them.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Delusional Disorder, Schizophreniform Disorders
- Trial name
- NCT03559426
- Testing
- Antipsychotic Reduction, Antipsychotic Maintenance
- Where
- United Kingdom
- Volunteers
- 253 people
- Sponsor
- University College, London
Parkinson's Disease Psychosis
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
Patients with Parkinson's disease (PD) sometimes experience symptoms affecting their movement, such as slowness, tremor, stiffness, and balance or walking problems.
- Trial name
- C-SAPP (NCT04373317)
- Testing
- Pimavanserin, Quetiapine
- Where
- 24 sites in United States
- Volunteers
- 358 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Obesity
Proper Nutrition, Physical Exercise and Appropriate Weight in Individuals With Long Term Mental Illness
Based on previous findings that mentally ill inpatients are interested in losing treatment associate weight gain and are capable of adhering to a weight reduction program, this study will investigate the effects of participation…
- Trial name
- NCT00474227
- Testing
- group therapy, physical exercise, nutrition lectures
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Lev-Hasharon Mental Healtlh Center
Schizophrenia, Impaired Cognition
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
The purpose of this study is to determine if EVP-6124 (an alpha-7 nAChR agonist) enhances the cognitive abilities of subjects with Schizophrenia who are also taking stable antipsychotic therapy.
- Trial name
- NCT01714661
- Testing
- EVP-6124
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 753 people
- Sponsor
- FORUM Pharmaceuticals Inc
Schizophrenia
A Study of the Effects of Paroxetine on the Pharmacokinetics of Paliperidone ER
The purpose of this study is to evaluate the effects of a CYP2D6 inhibitor, paroxetine, on the pharmacokinetics of a single dose of orally administered paliperidone ER and to evaluate the safety and tolerability of both…
- Trial name
- NCT00791713
- Testing
- Paliperidone ER
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Agitation,Psychomotor
Outcomes of Antipsychotic Medication Used in the Emergency Department
To review records of patients treated with antipsychotics (including Adasuve, Geodon, Haldol) in order to evaluate outcomes.
- Trial name
- OAMED (NCT02504450)
- Testing
- Adasuve, Alternative medications
- Volunteers
- 93 people
- Sponsor
- Wake Forest University Health Sciences
Schizophrenia, Bipolar Disorder
Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations
The purpose of this study is to build a data repository that can be used to understand pharmaceutical utilization patterns among patients being treated in community behavioral health organizations (CBHOs) for schizophrenia or…
- Trial name
- NCT01181960
- Testing
- Risperidone long acting injectable - New Starts, Risperidone long acting injectable - Continuous Users, Paliperidone Palmitate -New and Continuous Users
- Where
- 34 sites in United States
- Volunteers
- 1,066 people
- Sponsor
- Janssen Scientific Affairs, LLC
Schizophrenia
Effect of Genotyping for CYP450 Polymorphisms Versus Intense Clinical Monitoring on Antipsychotic Drug Treatment
The purpose of this study is to determine whether genotyping for CYP2D6 and 2C19 polymorphisms or intense clinical monitoring of treatment and adverse effects improves the antipsychotic treatment in patients with schizophrenia.
- Trial name
- NCT00707382
- Testing
- (1) Genotyping for CYP4502D6 and 2C19 polymorphisms, (2) Intense clinical monitoring, (3) Control
- Where
- Denmark
- Volunteers
- 311 people
- Sponsor
- Gesche Jurgens
Impaired Glucose Tolerance Associated With Drugs
Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients?
Metabolic disturbances, obesity and life-shortening cardiovascular morbidity are major clinical problems among antipsychotic-treated patients.
- Trial name
- GREAT (NCT01845259)
- Testing
- Liraglutide
- Where
- Denmark
- Volunteers
- 103 people
- Sponsor
- Psychiatric Centre Rigshospitalet
Psychosis
To Demonstrate the Relative Bioequivalency of Generic Haloperidol Tablets Versus Haldol in Normal Volunteers
To demonstrate the relative bioequivalency of generic Haloperidol tablets versus Haldol in normal volunteers.
- Trial name
- NCT00946491
- Testing
- Haloperidol 10 mg Tablets (Cord Laboratories), Haldol 10 mg Tablets (McNeil Pharmaceuticals)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sandoz
Posttraumatic Stress Disorder
An Open Label Pilot Study of Adjunctive Asenapine for the Treatment of Posttraumatic Stress Disorder
This is an open-label pilot study of adjunctive asenapine for the treatment of Posttraumatic Stress Disorder (PTSD) in veterans who have not fully remitted to an adequate trial of standard antidepressant treatment.
- Trial name
- NCT01587118
- Testing
- Adjunctive asenapine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Lori Davis, MD
Dementia
Dementia Antipsychotics And Antidepressants Discontinuation Study
The aim of this study is to discontinue antipsychotics and antidepressants, and to study its effect on Behavioural- and Psychological Symptoms in Dementia (BPSD).
- Trial name
- DESEP (NCT00594269)
- Testing
- Risperidone, Escitalopram, Citalopram
- Where
- 8 sites in Norway
- Volunteers
- 149 people
- Sponsor
- Sykehuset Innlandet HF
Schizophrenia, Schizophreniform Disorders
Investigating the Muscarinic System in Schizophrenia Using Positron Emission Tomography
Within the schizophrenia population, there are individuals that respond to first-line antipsychotic treatments while others do not.
- Trial name
- NCT06278246
- Testing
- PET Scan
- Where
- Canada
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia
Intramuscular Injections of Paliperidone Palmitate in the Arm or Buttock of Subjects With Schizophrenia
The purpose of the study is to compare the pharmacokinetic parameters (blood concentrations) of i.m. paliperidone palmitate after administration in 2 different injection sites (deltoid or gluteal).
- Trial name
- NCT00073320
- Testing
- Paliperidone Palmitate
- Volunteers
- 88 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Psychoses
Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
After one year neuroleptic maintenance treatment in patients with first episode schizophrenia, neuroleptic treatment will be continued vs. stepwise discontinued (randomized design) over a period of 1 year.
- Trial name
- NCT00159120
- Testing
- maintained antipsychotic treatment vs. stepwise drug discontinuation
- Where
- Germany
- Volunteers
- 71 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Schizophrenia, Schizoaffective Disorder
Characterizing Response to Antipsychotics in Schizophrenia
The goal of this research project is to develop MRI-based biomarkers to identify patients with schizophrenia who are most likely to benefit from first-line antipsychotic or clozapine treatment.
- Trial name
- NCT06159322
- Testing
- Olanzapine, Clozapine
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- The Royal Ottawa Mental Health Centre